

## KID Document

### Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

**Product**

Subscription option / Equity right

**ISIN**

DK0061672334

**PRIIP manufacturer (for the purposes of this document only)**

Nordic Issuing, Stortorget 3, 211 22 Malmö, Sweden. [www.nordic-issuing.se](http://www.nordic-issuing.se)

**Competent authority**

The Swedish Supervisory Authority (Finansinspektionen)

**Date of issuance**

2021-08-09

### Description of the product

A subscription option gives the holder the right to, in the future, subscribe for new shares in an issuer in exchange for remuneration. The subscription option in this case concerns DanCann Pharma A/S (“the Company”) which is listed at Spotlight Stock Market. The subscription option has ISIN DK0061672334 and is intended for retail investors as well as institutional investors.

### Risk section

The manufacturer of this financial instrument bases the issuance of the instrument on the current demand of this instrument in the market. The subscription option is a commonly traded instrument on the financial market. The assessment is made that the issued subscription option will not affect the integrity of the financial market. Furthermore, the assessment is made that the subscription option will not affect the function of the financial market. The subscription option has been generated with transparency and is considered as an uncomplicated financial instrument.

If a general deterioration takes place in the financial market, investors could demand lower valuation of the financial instruments. The issued subscription option hence is at risk of receiving a lower valuation. Though it is recalled that, if the financial market is generally affected by a deterioration, all financial instruments in the market will be affected.



If any possible risk at a counterparty to the issuer will be realized, there is a risk that the issued subscription option will be negatively affected. The subscription option is intended to reflect the financial situation of the issuer, which is why the subscription option might get affected by a counterparty risk.

If the subscription option does not become commercially viable, the risk of an inferior liquidity in the financial instrument could appear. This in turn could increase the volatility in the financial instrument.

Except from above mentioned scenarios, specific events in the financial market or in the company issuing the instrument might affect the financial instrument. Such specific events might affect the investors risk willingness, which could have impact on the financial instrument in question. Furthermore, political decisions might have effect on the financial instrument. Other scenarios, such as war, environmental catastrophes and other force majeure-scenarios could have impact on the financial instrument.

Nordic Issuing is subject to capital requirements stipulated by law and is in adequate solvency situation. For the event Nordic Issuing would enter into insolvency, the value of the financial instruments is protected through deposit insurance and investor protection ensured by the Swedish National Debt Office (Riksgälden).

## **Costs**

The financial instrument is not imposed with any costs or fees from Nordic Issuing. Eventual brokerage fees and/or fees charged by the financial institute that holds depots or accounts on behalf of the investor may occur.

## **Investment strategy**

The subscription option will not be tradeable. The holder of a subscription option will be able to subscribe for new shares in the company, by exercising the subscription option during the 14<sup>th</sup> of July 2022, until the 4<sup>h</sup> of August 2022. The subscription option will, if not exercised during above mentioned period of time, become void and lose its value. This means that the investor might lose the capital invested in the instrument when the instrument was obtained.

## **Complaints**

Complaints as a result of this instrument should be addressed to Nordic Issuing. If you are unable to reach an acceptable solution or are unsure if you have been treated correctly, you can contact the [Consumer Banking and Finance Bureau](#) or the [National Board for Consumer Disputes](#).

## **Additional information**

For the event additional information is required, this can be met by contacting [info@nordic-issuing.se](mailto:info@nordic-issuing.se)